UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equinix
EQIX
|
+$1.32B |
| 2 |
Digital Realty Trust
DLR
|
+$931M |
| 3 |
Western Digital
WDC
|
+$895M |
| 4 |
Simon Property Group
SPG
|
+$736M |
| 5 |
Realty Income
O
|
+$643M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$1.73B |
| 2 |
Eaton
ETN
|
+$1.21B |
| 3 |
Seagate
STX
|
+$1.1B |
| 4 |
Trane Technologies
TT
|
+$1.02B |
| 5 |
Accenture
ACN
|
+$1.01B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 40.05% |
| 2 | Financials | 11.12% |
| 3 | Healthcare | 9.54% |
| 4 | Consumer Discretionary | 9.09% |
| 5 | Communication Services | 8.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1676
QuidelOrtho
QDEL
$932M
| $4.09M | ﹤0.01% |
233,675
+36,714
| +19% | +$485K |
2017 Q3
35 quarters
|
|
1677
BancFirst
BANF
$3.72B
| $4.07M | ﹤0.01% |
36,646
-4,266
| -10% | -$478K |
2020 Q2
24 quarters
|
|
1678
Amneal Pharmaceuticals
AMRX
$7.47B
| $4.06M | ﹤0.01% |
234,773
-14,589
| -6% | -$200K |
2024 Q1
9 quarters
|
|
1679
FIVE9
FIVN
$2.77B
| $4.06M | ﹤0.01% |
190,612
-15,032
| -7% | -$297K |
2015 Q1
45 quarters
|
|
1680
Enliven Therapeutics
ELVN
$3.2B
| $4.06M | ﹤0.01% |
80,072
+12,597
| +19% | +$535K |
2024 Q2
8 quarters
|
|
1681
Northwest Bancshares
NWBI
$2.24B
| $4.06M | ﹤0.01% |
267,960
+38,205
| +17% | +$532K |
2013 Q2
52 quarters
|
|
1682
Flywire
FLYW
$2.33B
| $4.06M | ﹤0.01% |
231,114
-160,711
| -41% | -$2.37M |
2022 Q2
16 quarters
|
|
1683
SELLAS Life Sciences
SLS
$2.46B
| $4.04M | ﹤0.01% |
+273,403
| New | +$1.89M |
2026 Q2
0 quarters
|
|
1684
S&T Bancorp
STBA
$1.78B
| $4.03M | ﹤0.01% |
82,139
-2,761
| -3% | -$124K |
2014 Q1
49 quarters
|
|
1685
First Trust Technology AlphaDEX Fund
FXL
$2.83B
| $4.02M | ﹤0.01% |
18,518
-109
| -0.6% | -$21.2K |
2025 Q4
2 quarters
|
|
1686
RH
RH
$2.67B
| $4.01M | ﹤0.01% |
24,345
-11,159
| -31% | -$1.54M |
2013 Q2
52 quarters
|
|
1687
First Bancorp
FBNC
$2.68B
| $4.01M | ﹤0.01% |
62,717
-225
| -0.4% | -$13.3K |
2014 Q1
49 quarters
|
|
1688
Liberty Live Group Series A
LLYVA
$8.89B
| $4.01M | ﹤0.01% |
39,587
-1,903
| -5% | -$180K |
2023 Q3
11 quarters
|
|
1689
Greif
GEF
$4.73B
| $4M | ﹤0.01% |
53,744
-6,142
| -10% | -$412K |
2013 Q2
52 quarters
|
|
1690
Sarepta Therapeutics
SRPT
$2B
| $4M | ﹤0.01% |
222,496
-54,459
| -20% | -$1.03M |
2018 Q3
31 quarters
|
|
1691
Immunome
IMNM
$2.21B
| $4M | ﹤0.01% |
188,636
+1,625
| +0.9% | +$34.8K |
2024 Q1
9 quarters
|
|
1692
Tango Therapeutics
TNGX
$3.86B
| $4M | ﹤0.01% |
127,801
+52,084
| +69% | +$1.29M |
2025 Q4
2 quarters
|
|
1693
Wendy's
WEN
$1.17B
| $3.99M | ﹤0.01% |
481,357
-52,059
| -10% | -$372K |
2013 Q2
52 quarters
|
|
1694
Astrana Health
ASTH
$1.83B
| $3.98M | ﹤0.01% |
85,804
-8,923
| -9% | -$321K |
2019 Q4
26 quarters
|
|
1695
First Trust Morningstar Dividend Leaders Index Fund
FDL
$8.15B
| $3.98M | ﹤0.01% |
81,719
-40
| -0% | -$2K |
2025 Q4
2 quarters
|
|
|
1696
Accenture
ACN
$144B
| $3.97M | ﹤0.01% |
31,877
-5,789,472
| -99% | -$1.01B |
2013 Q2
52 quarters
|
|
1697
Quaker Houghton
KWR
$2.7B
| $3.95M | ﹤0.01% |
24,893
-522
| -2% | -$73.3K |
2013 Q3
51 quarters
|
|
1698
Schneider National
SNDR
$5.45B
| $3.93M | ﹤0.01% |
107,469
-21,834
| -17% | -$712K |
2019 Q2
28 quarters
|
|
1699
Stock Yards Bancorp
SYBT
$2.44B
| $3.9M | ﹤0.01% |
50,993
+2,335
| +5% | +$168K |
2018 Q2
32 quarters
|
|
1700
Addus HomeCare
ADUS
$2.26B
| $3.9M | ﹤0.01% |
38,808
-3,770
| -9% | -$356K |
2023 Q1
13 quarters
|
|
Similar funds
UBS AM's Q2 2026 Portfolio in Review
As of Q2 2026, UBS AM held 3,886 positions worth $550B, up 14% from $481B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
UBS AM's Q2 2026 filing shows 45 new, 996 increased, 1,636 reduced and 163 closed positions. Its largest new stake was Honeywell Aerospace: 1,676,062 shares worth $371M. The largest sale was Linde, an estimated $1.73B.
By sector, the portfolio is most concentrated in Technology at 40% of assets, up from 35% a quarter earlier, followed by Financials and Healthcare.
- UBS AM's largest Q2 2026 buy was Honeywell Aerospace: 1,676,062 shares worth $371M.
- UBS AM added most to Equinix in Q2 2026, an estimated $1.32B increase.
- UBS AM's biggest Q2 2026 reduction was Linde, cutting an estimated $1.73B.
- UBS AM fully exited Hologic in Q2 2026, selling an estimated $174M.
- UBS AM's ten largest holdings make up 33% of its $550B portfolio in Q2 2026.
- UBS AM opened 45 new positions and closed 163 in Q2 2026.
- UBS AM's portfolio value rose 14% quarter-over-quarter to $550B.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.